India Glycols Limited approved its Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025. The Board Meeting concluded on February 10, 2026. On a standalone basis, Profit After Tax for the quarter stood at ₹65.26 Crore. Consolidated total comprehensive income for the quarter was ₹67.32 Crore.
Board Approves Q3 FY2025 Results
The Board of Directors of India Glycols Limited convened on February 10, 2026, to consider and approve the Unaudited Financial Results for the quarter and nine months that ended December 31, 2025. The meeting commenced at 16:00 Hrs. and concluded at 17:12 Hrs.
Standalone Financial Highlights (Quarter Ended Dec 31, 2025)
The Standalone results show robust performance across the main revenue lines. Key figures for the quarter ended 31.12.2025 are:
- Income from operations: ₹2,551.06 Crore.
- Profit / (Loss) before Tax: ₹88.30 Crore.
- Profit / (Loss) for the period (PAT): ₹65.26 Crore (compared to ₹53.94 Crore in Q2 FY2025).
- Total comprehensive income for the period: ₹65.07 Crore.
- Basic Earning per share (Annualised): ₹10.42.
Consolidated Financial Highlights (Quarter Ended Dec 31, 2025)
The Consolidated results, which include the Group’s share of net profit from the joint venture, present the following quarterly figures:
- Total consolidated income: ₹2,551.84 Crore.
- Profit / (Loss) before Tax (including Joint Venture share): ₹90.61 Crore.
- Profit / (Loss) after tax (PAT): ₹67.57 Crore.
- Total comprehensive income / (loss) for the period: ₹67.32 Crore.
- Basic Earning per share (Annualised): ₹10.79.
Segmental Performance Overview (Consolidated)
The Bio-based Specialities and Performance Chemicals segment remains the largest contributor to revenue, although the Potable Spirits segment shows a healthy PBIT margin for the quarter at ₹72.43 Crore.
- The consolidated segment results (PBIT) for the quarter ended 31.12.2025 totaled ₹147.64 Crore.
- The consolidated total assets for the Group stood at ₹6,247.52 Crore as of the period end.
Key Corporate Updates
The notes accompanying the results detail several significant corporate actions that have impacted the figures:
- The Board approved a Composite Scheme of Arrangement in February 2025, focusing on the Demerger of the Bio Pharma undertaking and Spirits & Biofuel Undertaking. The NCLT allowed the first motion application on January 15, 2026.
- The company executed a Stock Split/Sub-division on August 12, 2025, changing the face value from ₹10 to ₹5 per share, requiring the restatement of all prior EPS data.
- A preferential allotment to raise funds aggregating up to ₹466.99 Crore was completed on November 24, 2025.
- An exceptional expense of ₹0.83 Crore was recorded due to the initial impact assessment of the new ‘New Labour Codes‘ effective from November 21, 2025.
Source: BSE
